| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8835646 | RECORDATI RARE | Organic compounds |
Aug, 2026
(2 years from now) | |
| US8314097 | RECORDATI RARE | Organic compounds |
Mar, 2029
(4 years from now) | |
| US9434754 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8609862 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(6 years from now) | |
| US10143680 | RECORDATI RARE | Pharmaceutical dosage forms |
Jul, 2035
(11 years from now) | |
| US10709691 | RECORDATI RARE | Pharmaceutical dosage forms |
Oct, 2035
(11 years from now) | |
Isturisa is owned by Recordati Rare.
Isturisa contains Osilodrostat Phosphate.
Isturisa has a total of 6 drug patents out of which 0 drug patents have expired.
Isturisa was authorised for market use on 06 March, 2020.
Isturisa is available in tablet;oral dosage forms.
Isturisa can be used as cushing's disease.
Drug patent challenges can be filed against Isturisa from 06 March, 2024.
The generics of Isturisa are possible to be released after 12 October, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2025 |
| Orphan Drug Exclusivity(ODE-286) | Mar 06, 2027 |
Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient
NCE-1 date: 06 March, 2024
Market Authorisation Date: 06 March, 2020
Treatment: Cushing's disease
Dosage: TABLET;ORAL
ISTURISA family patents
